Cutler Group’s Redhill Biopharma RDHL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Hold
0
5538
2022
Q1
Sell
-6
Closed -$14.2K 5897
2021
Q4
$15K Buy
6
+2
+50% +$8K ﹤0.01% 3365
2021
Q3
$17K Buy
+4
New +$27.1K ﹤0.01% 3501
2021
Q2
Hold
0
-$1K 6223
2021
Q1
Hold
0
5336
2020
Q4
Sell
-2
Closed -$18K 5379
2020
Q3
$16K Hold
2
﹤0.01% 2653
2020
Q2
$12K Hold
2
﹤0.01% 2760
2020
Q1
$11K Hold
2
﹤0.01% 2668
2019
Q4
$9K Buy
2
+1
+100% +$6.39K ﹤0.01% 2707
2019
Q3
$9K Buy
+1
New +$7.28K ﹤0.01% 2695
2019
Q2
Hold
0
3953
2019
Q1
Hold
0
3436
2018
Q4
Hold
0
3681
2018
Q3
Hold
0
3557

Other funds holding RDHL

Cutler Group's RDHL Position: Q2 2022 in Review

Cutler Group held its Redhill Biopharma (RDHL) position steady in Q2 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5538.

Cutler Group first reported a position in RDHL in Q3 2019 and has held it in 7 quarters since. The position peaked at $17K in Q3 2021. 44 funds tracked by Wall St. Rank hold RDHL as of Q2 2022.

  • Cutler Group held 0 shares of Redhill Biopharma worth $0 as of Q2 2022.
  • Cutler Group left its Redhill Biopharma share count unchanged in Q2 2022.
  • Redhill Biopharma made up ﹤0.01% of Cutler Group's portfolio in Q2 2022, its #5538 holding.
  • Cutler Group first reported a position in Redhill Biopharma in Q3 2019 and has held it in 7 quarters since.
  • Cutler Group's Redhill Biopharma position peaked at $17K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.